This article is more than 5 years old. Information may no longer be current.
Study shows bepotastine ophthalmic solution reduces nasal symptoms
Click Here to Manage Email Alerts
PHOENIX – Study results presented in a poster here at Academy 2012 showed that bepotastine besilate ophthalmic solution 1.5% was superior to placebo at improving nasal symptoms of allergic rhinitis over a 2-week period.
Williams and colleagues said that allergic rhinitis shares similar pathophysiologic mechanisms with allergic conjunctivitis, which affects up to 40% of the U.S. population. More than half of patients with allergies experience both allergic rhinoconjunctivitis and ocular symptoms.
Bepreve (bepotastine besilate ophthalmic solution 1.5%, Bausch + Lomb) is approved by the U.S. Food and Drug Administration for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.
The study involved 245 patients at least 12 years old who were randomized to receive Bepreve or placebo twice daily for 2 weeks. Nasal symptoms were assessed and recorded twice daily.
The researchers found Bepreve to be superior to placebo in reducing the time to improvement in both instantaneous total nasal symptom score and reflective total nasal symptom score. The safety profiles of Bepreve and placebo were similar, they added.
Disclosures: All authors are employees of Bausch + Lomb.